Medicare drug prices pegged to global benchmarks—but only for some

What it does

This bill requires Medicare and Medicaid to test a 'Most Favored Nation' drug pricing model starting January 1, 2029, where pharmaceutical manufacturers must offer U.S. patients the second-lowest price that the drug sells for in eight wealthy countries (Canada, Denmark, France, Germany, Italy, Japan, Switzerland, UK). Manufacturers can avoid this requirement by signing a separate agreement with the government committing to increase U.S. manufacturing operations. The test runs for 5 years and applies to drugs covered by Medicare Part B, Part D, and Medicaid.

Why we flagged it

The bill's core mechanism is a regulatory price-control model that ties U.S. Medicare/Medicaid reimbursement to the second-lowest price in eight OECD countries. This is a direct intervention in pharmaceutical pricing, not a market-based or voluntary mechanism.

What the text implies

• The 'covered agreement' escape clause (allowing manufacturers to opt out if they commit to U.S. manufacturing) creates a de facto industrial policy incentive—manufacturers may relocate production to avoid price controls, shifting supply-chain risk and potentially raising costs elsewhere.
• The model applies only to drugs sold in at least 2 of 8 reference countries, potentially excluding rare or newly approved drugs, creating a two-tier system where some patients have price protections and others do not.
• The 5-year pilot window (2029–2034) is short for measuring long-term effects on drug innovation, market entry, or manufacturing decisions; results may be incomplete when Congress decides whether to expand or terminate the program.
• Manufacturers may respond by raising prices in reference countries to reduce the 'second-lowest' benchmark, shifting the cost burden internationally rather than absorbing U.S. price reductions.
• The bill does not address how the model interacts with existing rebate, discount, and negotiation programs under the Inflation Reduction Act, creating potential overlap or conflict in pricing authority.

Who it affects

Ordinary Americans with Medicare and Medicaid coverage would pay substantially lower drug prices—pegged to international reference prices rather than current U.S. list prices, which are typically 2–3× higher than in peer nations. This directly reduces out-of-pocket costs and premiums for seniors and low-income patients, though the benefit is limited to those already enrolled in these programs.

Who stands to gain

• Medicare beneficiaries (seniors)
• Medicaid beneficiaries (low-income individuals)
• Pharmacy benefit managers (if they capture savings)
• State Medicaid programs (reduced drug spending)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Center for Medicare and Medicaid Innovation (CMMI), Pharmaceutical manufacturers, Medicare Part B, Part C, Part D, Medicaid, Reference countries: Canada, Denmark, France, Germany, Italy, Japan, Switzerland, United Kingdom

Where it stands

• Mar 5, 2026 — Introduced · Congress.gov: “Introduced in House”
• Mar 5, 2026 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

8 lobbying clients named this bill on 8 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $13,160,000 in lobbying spend. A filing names 30 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 88% of bills with at least one filing.

Daniel Meuser, the sponsor, reported $835,786 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $7,360,000 on 1 filing
• Amgen Inc — $2,440,000 on 1 filing
• Pfizer Inc. — $1,880,000 on 1 filing
• Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing
• Grifols Shared Services North America Inc — $370,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.